CoinMarketCap Data Accountability and Transparency Alliance

CoinMarketCap

Cryptocurrency-price tracker CoinMarketCap has issued a post urging exchanges to provide mandatory data by June, or else they will be removed from its calculations.

The crypto-data source celebrates its 6th birthday today and announced a list of “major initiatives” as part of its celebrations.

CoinMarketCap: Data Accountability and Transparency Alliance

The site listed five major initiatives that it has been working on for months. They are as follows:

Data Accountability & Transparency Alliance
Block Explorers
Shop
API Revised Plans
Mobile Apps

The first initiative—Data Accountability and Transparency Alliance—is the most eye-catching as …

Get latest cryptocurrency news on bitcoin, ethereum, initial coin offerings, ICOs, ethereum and all other cryptocurrencies. Learn How to trade on cryptocurrency exchanges.

All content provided by Crypto Currency News is subject to our Terms Of Use and Disclaimer.

Share:

More Posts

AAPL – Apple might unveil the new iPad Pro in a digital event on April 20th

Apple Inc (NASDAQ: AAPL) said on Tuesday it will reveal new versions of several products, including AirTags and iPad Pro, in a virtual event on April 20th. The event, as per the tech giant, will start at 1 p.m. easter time.
Apple shares opened roughly 1% up in the stock market on Tuesday and gained another 1.5% later in the day. The U.S. firm is now exchanging hands at £97.80 per share. In comparison, it had started the year 2021 at a lower £94.15 per share.
Apple’s iPad revenue jumped 41% in the recent fiscal quarter

Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

Apple’s iPad revenue jumped 41% in the fiscal first quarter to £6.14 billion as the ongoing Coronavirus pandemic fuelled demand. The launch of the new iPad Pro that is likely to come with Apple’s latest and fastest processor is expected to help the American multinational benefit further from the outbreak-driven increase in demand.
Apple’s new iPad Pro might also pack a new screen that relied on mini-LED technology for an enhanced experience while viewing photos or watching movies. The Cupertino-based company had launched its current iPad Pro last year in March along with the Magic Keyboard for a more laptop-like experience.
In separate news from the United States, Jefferies upgraded Booking Holdings stock on Tuesday from ‘hold’ to ‘buy’ as the global travel and tourism sector shows signs of recovery after a massive hit from the COVID-19 crisis.

Tip: looking for an app to invest wisely? Trade safely by signing-up with our preferred choice,
eToro:

visit & create account

Apple might also refresh AirPods and iMac in the upcoming event
Apple Inc hasn’t refreshed AirPods since March 2019, and the iMacs haven’t been updated with the new M1 processor. So, a new version of these devices might also be on the way. Ming-Chi Kuo (top Apple analyst), however, said last month that the iPhone maker might not release its new AirPods until Q3 of the ongoing year.
Apple TV, on the other hand, is long overdue to see an upgrade. It was launched in 2015, followed by a minor update in 2017. In a report published in December, Bloomberg said Apple was planning an update that is expected to introduce a new processor, a new remote, and a greater focus on gaming.
Apple Inc. performed largely upbeat in the stock market lasts year with an annual gain of more than 75%. At the time of writing, the American multinational technology company has a market cap of £1.64 trillion and a price to earnings ratio of 36.25.

VIAC – The ViacomCBS Revival Is the Turnaround Story You Can't Ignore

ViacomCBS (NASDAQ:VIAC, NASDAQ:VIACA) shares have been hammered on the unwinding of a massive position by Archegos Capital. The entertainment conglomerate has lost more than 50% of its market capitalization since mid-March. But despite what the market says, VIAC stock isn’t fundamentally broken.

Source: Jer123 / Shutterstock.com

In fact, the blowup has created a perfect opportunity to buy VIAC shares now.
VIAC Stock: Base Hits Win Ball Games
If you’re tired of seeing your teenager’s Dogecoin (CCC:DOGE-USD) rise 500% for no reason, stocks like ViacomCBS tell us one thing: “slow and steady” investing still wins in the long run. Over the past 12 months, ViacomCBS stock has risen 163%, beating hot names like Sundial (NASDAQ:SNDL) and other popular Reddit stocks.
VIAC stock has always been somewhat expensive; purchases by a mysterious entity (now unmasked as Archegos Capital) pushed VIAC up to $100 — a 36x EV-to-EBITDA valuation. But the shares’ sudden 50% reversal provides investors with a rare chance to buy into one of media’s most underrated turnaround stories.
Since the company’s merger with CBS in December 2019, the media giant has faced all sorts of challenges — from having to integrate a huge acquisition, to dealing with the coronavirus pandemic, to shifting its business model to focus on streaming. And, the numbers don’t tell a good story. The TV dinosaur — whose broadcast lineup includes such properties as Nickelodeon and Comedy Central — is getting steadily devoured by streaming titans Netflix (NASDAQ:NFLX), Amazon (NASDAQ:AMZN), Disney (NYSE:DIS) and Apple (NASDAQ:AAPL).
“Cord cutting” has resulted in a precipitous decline of pay-TV households, with cable subs expected to bottom out at 50 million over the next 5 years. While ViacomCBS claims 19.2 million viewers, Netflix has over 203 million paid global subscribers. Just to add a bit more salt in the wound, Netflix is also is adding newcomers to the tune of over 8 million per quarter. Amazon and Disney+ are closely behind, at 150 million, and 100 million, respectively.
More Than a Numbers Game
With this wide a gap, no one expects Viacom to catch up to Netflix. But the company doesn’t have to catch up. It just needs to start running faster.
In March 2019, Viacom did just that by acquiring free, ad-supported streaming TV platform Pluto TV, adding 12 million subscribers. Last month, it rolled out a more comprehensive streaming service called Paramount+. The service features a catalog of more than 30,000 episodes, 2,500 movie titles and over 1,000 live sporting events, plus around-the-clock news coverage. Early subscriber figures are still hazy, but totaled around 8 million as of November.

On the surface, Viacom’s streaming strategy might look too little too late. But investors need to remember that this is a turnaround story. Winning isn’t necessary. If the company can effectively “run in place” with its cableTV business — or at least, slow the pace of its decline — it has a real shot at converting these subscribers onto its streaming platform. A combination of live news and sports, combined with subscriber inertia and laziness, can keep a diminished bundle alive long enough for Viacom to transform the business.
Doubters can look at Disney. In October of last year, the company announced a restructuring of its media and entertainment businesses in order to focus on streaming. Disney’s stock has since jumped 34%.
Gateway to the Good Stuff
CBS is still the most watched TV network in the U.S. Almost 6 million viewers tune in for Paramount, Nickelodeon and NFL football. This base gives Viacom a good head start in converting its users to streamed content. Pluto TV is essentially a gateway, luring subscribers in with free content with the hope of converting them into paying subscribers of Paramount+. It also gives Viacom access to a growth demographic — a much younger audience than a typical pay-TV subscriber.
Viacom has already started this conversion process with Showtime by unlocking a selection of programming for free on PlutoTV. The company will also stock Paramount+ with original series related to existing franchises including The Godfather and SpongeBob SquarePants.
More Than Running in Place
No doubt, it’s still early. But Viacom’s recent performance proves the strategy can work. In Q4, the company reported 19.2 million U.S. streaming subscribers, up 71% year over year. And Viacom thinks it can run faster still, targeting 65 to 75 million streaming subs by 2024. To do this, the company is following industry leader Netflix’s playbook: invest in high-quality original content and hopefully come up with a zeitgeist-capturing hit show. A $5 billion content investment goal through 2024 should help, as will cash from its recently completed $3 billion convertible offering.

Every step Viacom makes toward steering the business toward streaming has a huge impact on the financial model. For every cable TV subscriber that doesn’t cancel their cableTV service, the company can redirect this cash flow toward its streaming growth engine. Add to that steadily improving metrics in the cable TV business, and you start to see evidence of a sustainable turnaround.
In fact, Viacom posted solid Q4 results. A 4% climb in advertising revenue in the quarter and a 13% climb in affiliate revenue are nothing to sneeze at.
Let’s Not Throw the Baby Out With the Bathwater
With an appetite for content clearly in place and money to burn, Viacom has a legitimate shot at transforming its business. Winning isn’t necessary. Not every cable subscriber has to become a streaming subscriber.
In order for the long-term case in ViacomCBS stock to work, the company just needs to show there’s a new growth engine in place that looks more like Netflix, and less like a dinosaur. As the company’s streaming services continue to gain traction, VIAC shares should see significant multiple expansion.
The stock offers a combination of reasonable growth targets and an attractive valuation. At 11x forward earnings — a discount to the sector medium at over 21x — the bar is set very low.
Longer-term, we see a path for VIAC stock to be worth $70 or more, driven by the company’s push into streaming and the value of its media assets.
On the date of publication, Joanna Makris did not have (either directly or indirectly) any positions in the securities mentioned in this article.
Joanna Makris is a Market Analyst at InvestorPlace.com. A strategic thinker and fundamental public equity investor, Joanna leverages over 20 years of experience on Wall Street covering various segments of the Technology, Media, and Telecom sectors at several global investment banks, including Mizuho Securities and Canaccord Genuity.

NKE – Xtep Clan's Fortune Returns To $1 Bln As Nike Backlash Spurs China Sneaker Shift

A China footwear clan’s fortune has returned to billionaire terrain amid shows of support for domestic brands in the country after a Nike statement last month expressed concern about alleged forced labor practices its Xinjiang region.

Shares in Xtep International Holding soared by 15.2% at the Hong Kong Stock Exchange yesterday to HK$5.99, their best close in more than two years.  That left Xtep’s controlling Ding family’s combined 53% stake in the business worth $1 billion.
Founded in 2001, Xtep supplies running shoes and sportswear. Among family shareholders, Ding Shui Po is the chairman and CEO, his sister Ding Mei Qing is an executive director and vice president, and brother Ding Ming Zhong is also an executive director and vice president.

Xtep shares traded at a recent closing low of HK$3.45 on March 10, shortly before an undated Nike statement saying it was “concerned about reports of forced labor” in Xinjiang surfaced. Nike, which doesn’t source products in Xinjiang, has since been faced a backlash on social media and boycott calls in China. China is the world’s second-largest cotton producer, and Xinjiang accounts for nearly 90% of its output, according to the government-published Shanghai Daily.  Nearly 70% of Xinjiang’s cotton is machine-picked, the newspaper said.

Shares in Xtep rivals Anta, Li Ning, and 361 have also gained since mid-March.
Mainland China is second only to the United States as home to the world’s largest number of billionaires.

See related posts:
Alibaba Alum Joins World Billionaire Ranks
@rflannerychina

JNJ – The Margin: Johnson & Johnson vaccine pause: What to know if you got or scheduled the shot

The COVID-19 vaccine rollout over the past few months has left people with plenty of questions, and the latest concerns about Johnson & Johnson’s single-dose vaccine have probably given folks even more.  We’re here to help. 

The background: The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) released a joint statement on Tuesday morning, recommending a temporary halt in the distribution of Johnson & Johnson’s
JNJ,
-1.28%
COVID-19 vaccine while they examine six severe cases of rare blood clots that have been reported in people who have received the shot. Health officials called for this short-term stoppage out of “an abundance of caution,” they said, emphasizing that these blood clots were “extremely rare,” and have only happened in less than one in a million vaccinated people. Specifically, just six cases of these rare blood clots have been reported among the 6.8 million Americans who have received the J&J single-dose vaccine. But the CDC wants to ensure that healthcare providers are prepared to treat blood clots if they occur. Read more: U.S. recommends pausing use of J&J’s COVID-19 vaccine after reports of rare blood clots So what happened? In these six cases, all of them women, a type of blood clot called a cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (aka thrombocytopenia). One person remains in critical condition, and one died.  Dr. Reynold Panettieri, a pulmonary physician and a professor of medicine at Rutgers University, explained to MarketWatch that a CVST manifests as a stroke. “Blood clots form in the draining veins of the brain, and that backs things up and causes bleeding into the brain,” he said. They’re rare, occurring in five in a million people each year, and can be caused by certain cancers or sickle cell disease.   All six recorded cases of CVST and low blood platelet levels amongst the J&J vaccine recipients  involved women between the ages of 18 and 48, with symptoms presenting six to 13 days after vaccination. But health officials noted that the number of these cases is so small, that they cannot generalize yet on whether this is something women of a certain age, or other demographic groups, could be at a higher risk of developing. This is why the CDC’s Advisory Committee on Immunization Practices, which recommends use of vaccines after the Food and Drug Administration authorization, will meet Wednesday to review the cases.  Coronavirus Update: U.S. COVID vaccine program faces setback with J&J jab, as experts say there is no cause for alarm The AstraZeneca
AZN,
-0.53%
COVID-19 vaccine, which has not been authorized in the U.S. yet, has been halted in some European countries over similar rare blood clot concerns. This news could understandably raise alarm in those people who have already received their J&J vaccine, however, or those who are scheduled to get their shots soon. But there’s no need to panic; just pay attention to whether you have symptoms such as a severe headache, abdominal pain, leg pain or shortness of breath. If you do, seek medical attention.  So this is what we know about these J&J cases so far, what symptoms people should watch out for, and what you should do about any upcoming J&J vaccine appointments. Keep in mind that this information is subject to change as we learn more, so these guidelines will be updated as health officials update their recommendations. I’ve already received my J&J shot. What should I watch out for?  The CDC and FDA say that if you suffer a severe headache, feel abdominal pain or leg pain, or start experiencing shortness of breath within three weeks after getting your J&J vaccine, you should seek medical attention or speak to your health care provider.  These blood clot symptoms should not be confused with the flu-like symptoms (fever, body aches, chills, fatigue and nausea) or swollen lymph nodes under your arms and near your collarbone, which can be a normal response to getting any of the COVID vaccines from J&J, Pfizer
PFE,
+0.45%
or Moderna
MRNA,
+6.35%.
  It should be noted that the blood clot events usually occurred about a week after the J&J vaccine, and no longer than three weeks after vaccination, with a median of about nine days. So if it’s been almost a month since you got your shot, then you should be in the clear.I’m scheduled to get my J&J shot. Should I cancel my appointment, or get the Pfizer or Moderna vaccine instead?  There is no need for you to rush to cancel your appointment, although your state or vaccination site may already be canceling or rescheduling J&J appointments for now while the recommended pause is in effect. Retailers and drugstores such as Walgreens, Rite Aid
RAD,
-5.07%,
CVS
CVS,
-0.19%
and Wegmans have canceled their J&J appointments for the time being, for example.  Or some states, including New York and Texas, will switch to giving those people scheduled to get the J&J shot one of the other available COVID vaccines from Pfizer and Moderna, instead. Check your local health department or your vaccination site for guidance. And the pause “will not have a significant impact” on the White House’s vaccination plan, according to Jeff Zients, the White House’s COVID-19 response coordinator. What’s more, doctors and vaccination sites can still give you the J&J vaccine. “This is a recommendation, and it’s not a mandate. It’s out of an abundance of caution,” Dr. Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research, said in a press conference on Tuesday. “If an individual health care provider has a conversation with an individual patient, and they determined that the benefit risk for that individual patient is appropriate, we’re not going to stop that provider from administering the vaccine.”  Keep in mind that tens of millions of people have already received the J&J vaccine without this severe side effect. “We have to put this into context,” said Panettieri. “It’s very important to realize that millions of people have gotten Johnson & Johnson vaccines, and have reaped the benefits of the vaccine. This is an incredibly uncommon and rare event. You’re more likely to get COVID-19 and have a serious COVID infection [if you don’t get vaccinated] than to get this complication from the vaccine.”  Who is most at risk of developing this rare blood clot/low platelet reaction from the J&J vaccine?  There are still too few cases to make any concrete connections. “Review of six is difficult to make generalizations from. We’re going to have our expert committee take a careful look,” Dr. Anne Schuchat, principal deputy director of the CDC, said during a press briefing Tuesday. “The numbers are quite small, small enough that it’s hard to generalize, but large enough that we wanted to take the action with the pause.”  Some things the cases do have in common so far, however: All six involved women between the ages of 18 and 48 years old, who developed the clots within six to 13 days of getting the J&J shot. But it’s far too soon to say that women of a certain age are at higher risk than anyone else.  But again: these blood clots are still extremely rare, and it is not at all clear whether the vaccine caused these clots. Using oral birth control pills and smoking cigarettes can also raise the risk of blood clots. “The likelihood of you having a CVST could occur from many, many more factors that people are exposed to than just this vaccine,” said Panettieri. “And remember, this kind of thrombosis occurs in five in a million people anyway. So when you’re starting to vaccinate millions and millions of people, you’re going to get some people who would have just developed this in any case.” How long will the J&J shot be on pause? What happens next?  Dr. Janet Woodcock, the FDA’s acting commissioner, said that this pause should only last “a matter of days” during a press briefing on Tuesday morning. This could change depending on “what we learn in the next few days,” she noted.  The CDC’s Advisory Committee on Immunization Practices will hold an emergency meeting on Wednesday from 1:30 to 4:30 p.m. ET to review the cases, and this meeting will be open to public viewing. Click here for more details about tuning in; no registration is required.  The bottom line: If you’ve received the J&J vaccine, keep an eye out for symptoms of this rare blood clot, including a severe headache, abdominal or leg pain, and shortness of breath within three weeks of getting your shot. But these blood clots are so rare — being recorded in less than one in a million people who’ve received their J&J shots — that there is no need to panic or rush to cancel an upcoming J&J vaccine appointment. Your vaccination site or local health department may be rescheduling appointments or swapping J&J vaccines for other vaccines, however, so check with your vaccination site to see how this could impact your future appointment.  “The takeaway message here is, the single most important thing people can do is get vaccinated,” said Panettieri. “Not to get vaccinated would put you at such an enhanced risk of death from COVID, or serious risk from COVID, that I would not be worried about these isolated and very rare cases of blood clots.”